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This study is a retrospective analysis of 39 consecutive patients 
who had a prothrombin time of over 25 seconds with respect to 
the bleeding complications. This study finds that the overall risk 
of bleeding is low, 2/39 (5.1%), that there is no statistical 
difference in the values of the patients who bled when compared 
to those who did not, and that patients who bled tended to have 
a clearly identifiable precipitating event. 
Introduction 
The prothrombin time (PT) has long been the standard mea-
surement of the degree of anticoagulation achieved in patients 
on oral anticoagulants, notably warfarin (Coumadin). This has 
been used as a predictor of the risk of bleeding. A PT within the 
range is regarded as safe, and aPT above the range as dangerous. 
Many patients are put through unrealistic regimens and frequent 
venous punctures just to manipulate the PT up or down 1 or 2 
seconds. The use of the international normalized ratio (INR) 
allows for elimination of interlaboratory variations, but the same 
premise is unchanged. This study analyzes the incidence of 
bleeding in a group of patients who had aPT of over 25 seconds 
as recorded by a local hospital hematology laboratory over a 
randomly chosen period of 3 months. This study attempts to 
evaluate just how risky it is to have an elevated PT, the nature of 
the bleeding events and whether the risk increases linearly with 
the magnitude of the PT. 
Materials and Methods 
A request was made to the director of the hematology labora-
tory of Straub Clinic and Hospital to randomly choose a 3 month 
period and identify all patients in this period who had a PT of 
over 25 seconds. A retrospective analysis was made of the 
patients' clinic and hospital charts to obtain the incidence and 
nature of any bleeding events. The period empirically chosen 
was January 1 to March 31, 1992 and the analysis was made in 
July 1992. 
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Results 
A total of 39 patients were identified as having aPT of over 25 
seconds. They all were on warfarin. The laboratory had not 
adopted INR at that time and the values are, therefore, unavail-
able. The patient characteristics, the PT values, and the nature of 
the bleeding events are shown in Tablet. 
The mean age of the patients was 63 years ±13 years. The most 
common indication for anticoagulation was deep vein 
thrombophlebitis, occuring in 15 out of39 patients (38%), 5 of 
whom had concurrent pulmonary embolism. Two patients were 
anticoagulated for pulmonary embolism alone. The next most 
frequent indication was atrial fibrillation, with 7/39 (18%), 
followed by transient ischemic attack (10%), stroke (10%), 
valve replacement or repair (7. 7% ), and vascular graft thrombosis 
(5.1%). Less common indications include cardiomyopathy, 
arterial embolism, post thrombotic syndrome, and hypercoagu-
lable state, each with 1139 (2.6% ). 
In 20 of these patients, the PT values were obtained during 
chronic warfarin therapy; in the rest, the PT values were re-
. corded sometime during initiation of warfarin. In 4 of these 
patients (No 1, 24, 29, 39), the elevated PT values were obtained 
within 1 week of initiation of therapy. Patients No 1 and 39 also 
were on heparin. 
Two patients (No 19 and 38, Table 1) had a bleeding event. 
The first p~tient was a 58-year-old woman with blue-toe 
syndrome, aortoiliac embolization requiring warfarin. The PT 
was recorded to be 26.2 seconds and 26.9 seconds on 2 separate 
days. She developed a thigh hematoma secondary to trauma, 
which resolved without specific therapy. 
The second patient was a 78-year-old woman who suffered a 
right hip fracture during a fall, and she underwent hip replace-
ment on the same day. Five days postoperatively, she exhibited 
hypoxemia with pulmonary embolism and left leg deep vein 
thrombophlebitis, necessitating the use of warfarin and an 
inferior venal caval filter. Her PT was documented to be as high 
as 34.9 seconds. She had bleeding into her right hip requiring 
transfusion and Vitamin K. She did well on conservative man-
agement. 
Discussion 
The incidence of bleeding in this group of 39 patients with aPT 
~25 seconds was 5.1 %. This is at the lower limit of the incidence 
of bleeding of all patients on warfarin in the literature (1.2% to 
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TABLE 1.- Characteristics of Patients with Prothrombin Time ~25 Seconds 
Pt No. Age/Sex Diagnosis Indication PTin Sees Bleeding Occurred 
1 81/M CVA,CA DVT 27.8 
-
2 78/M CM,AF AF 27.5 
-
3 82/M HTN,CVA CVA 26.0 
-
4 73/M AF, TIA AF,TIA 26.6 
-
5 77/M DM,HTN,CVA DVT 28.3 
-
6 77/M CAD,CA DVT,PE 33.7 -
7 86/M AMI AF 25.1 
-
8 65/M CA DVT,PE 27.1 
-
9 71/M HTN,DM,CVA AF 36.9 
-
10 58/M PLT DVT,PE 28.3 
-
11 52/M MVr MVr 25.4 
-
12 78/M CVA AF 26.1 
-
13 72/F CA DVT 33.8 
-
14 65/F MVR MVR 25.4 
-
15 75/F AAA AF 26.0 
-
16 63/F CA DVT 39.8 
-
17 83/F CAD AF,CVA 34.4 
-
18 78/F CA DVT 25.9 
-
19 58/F AE AE 26.9 thigh hematoma 
20 39/F DM,RF,PVD GT 27.7 
-
21 37/M TIA TIA 28.3 
-
22 70/M DVT DVT 25.2 
-
23 70/M COPD, CVD TIA 44.0 
-
24 80/M OM, CVA CVA 28.2 
-
25 64/M CM,CAD CM 47.3 
-
26 42/M DVT DVT 34.7 
-
27 70/F HTN,CAD DVT 39.4 -
28 62/M CVA, TIA TIA 30.9 
-
29 47/F DM,PVD,CVA GT 41.4 
-
30 80/F MVR MVR 34.1 -
31 56/F DVT,PE DVT,PE 26.4 
-
32 67/F PTS PTS 39.9 -
33 38/M HIV HC 26.2 -
34 73/F DVT DVT 28.8 
-
35 65/M DVT DVT 38.2 
-
36 63/F PE PE 28.3 
-
37 70/F AF,HTN,PVD AF 60.7 
38 78/F HF, HR DVT,PE 34.9 bleeding hip 
39 62/M HTN CVA 28.2 
Total 67±13 32.3±8.5 
Abbreviations 
AAA=abdominal aortic aneurysm, AE=arterial embolism, AF=atrial fibrillation, AMI=acute myocardial infarction, CA=earcinoma, 
CAD=coronary artery disease, CM=cardiomyopathy, COPD=ehronic obstructive lung disease, CVA=cerebrovascular 
accident, CVD=cerebrovascular disease, DM=diabetes mellitus, DVT =deep vein thrombophlebitis,· GT =graft thrombosis, 
HC=hypercoagulable state, HF=hip fracture, HIV=human immunodeficiency virus disease, HR=hip replacement, 
HTN=hypertension, MVR=mitral valve replacement, MVr=mitral valve repair, PE=pulmonary embolism, PTS=postthrombotic 
syndrome, PVD=peripheral vascular disease, TIA=transient ischemic attack 
-
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42.4%).1 The PT for the entice group was 32.3 ±8.5 seconds 
(mean ±1 standard deviation). It is notable that the mean PT of 
the 2 patients who bled was actually higher than the mean PT of 
the remaining 37 who did not (30.9 ±5.7 versus 32.4 ±8.7 
seconds, re~pectively). The lack of a linear relationship between 
the magnitude of the PT and the actual bleeding risk is further 
highlighted by the fact that there was no bleeding at all in the 
patients with the highest PTs (3 over 40 seconds, 1 over 50 
seconds, and 1 over 60 seconds). Despite the advanced age in 
this high risk group, with its attendant predisposition to ischemic 
cerebrovascular disease,1•2 there was no intracranial hemor-
rhage. Demonstrating the PT in INR values rather than seconds 
may smooth out some fluctuations in individual values, but these 
findings should not be significantly affected. In the majority of 
these patients, the PT values were obtained at least 1 week after 
initiation of therapy and should not reflect spuriously high 
values related to the early depletion of the clotting factors with 
shorter half-lives (for example, factor vn with a half-life of 6 
hours). Only 2 patients were on heparin concurrently, and 
neither of these patients bled. 
The 2 patients who bled had a clearly identifiable precipitating 
cause: Prior hip surgery or physical trauma to the thigh. It may 
be inferred that bleeding from anticoagulants is relatively un-
common without a precedent cause or precipitating factor. 
Frequently in medicine, there is a near religious or fanatical 
faith in numbers, as in drug levels or therapeutic ranges. The 
presence of a therapeutic range virtually binds the physician 
to doing everything humanly possible to keep the patient in 
range, frequently without prior knowledge or interest of how 
such values are determined in the first place, and without 
appreciation that no 2 patients are alike. The notion of 
something that can be defmed in seconds implies precision, 
and the availability of a fixed range promises effectiveness 
and safety. In the case of PT and warfarin, it has been shown 
that in patients with higher INR, the risk of bleeding is 
increased. •.3 This is, however, far from being an ali-or-none 
phenomenon, as this study demonstrates. The value of a high 
PT in predicting bleeding is in reality very poor. In a major 
study comparing 2 levels of anticoagulant intensities in 
patients with prosthetic heart valves, it was actually the 
minor bleeding that was increased with the higher INR, with 
no stastistical difference in major bleeding (bleeding requir-
ing transfusion) among the 2 groups.3 It might be more 
important to be cognizant of the established risk factors of 
bleeding with warfarin therapy (age ~5 years, female, 
history of gastrointestinal bleeding, stroke, atrial fibrillation, 
recent myocardial infarction, congestive heart failure, renal 
insufficiency, alcoholism. cancer or severe anemia).4 It is 
perhaps wiser to lessen the dosage in these patients, with 
tighter control of the PT rather than to accept a blanket 
therapeutic range for all patients-high or low risk. It is quite 
probable that a high-risk patient would bleed despite strict 
control, and a low-risk patient easily tolerates a PT of, for 
example, 35 seconds or an INR of 9. 
Even though less intense warfarin therapy could reduce the 
risk of bleeding, the current system of PT measurement (be 
it by seconds or by INR) as an index ofbleeding risk is far less 
-
precise than the term "therapeutic range" implies. Alternate 
parameters should be sought, for example, monitoring the native 
prothrombin antigen. 5 These, together with an astute awareness 
of risk factors and potential precipitating causes, can serve to 
ultimately diminish the bleeding risk of patients on warfarin. 
Conclusion 
Prothrombin time has long been the standard by which antico-
agulant activity and bleeding risk with warfarin have been 
measured. This study demonstrates that the magnitude of the PT 
itself had a very low predictive value for bleeding events, that 
most patients with high PT did not bleed, and that bleeding was 
generally related to a clear predisposing factor. This also sug-
gests the need for a more sensitive risk index than that afforded 
by PT and an awareness of high risk subgroups rather than blind 
adherence to a therapeutic range. 
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